Trial Profile
A 4-Part, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult, Elderly and Japanese Subjects, and the Pharmacodynamics in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2022
Price :
$35
*
At a glance
- Drugs Irsenontrine (Primary)
- Indications Dementia; Lewy body disease
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Eisai Inc
- 20 Jul 2017 Results of safety, tolerability and pharmacokinetics presented at the Alzheimer's Association International Conference 2017.
- 20 Jul 2017 Results of PK/PD modelling of E2027 presented at the Alzheimer's Association International Conference 2017
- 23 Dec 2016 Status changed from recruiting to completed.